WesBanco Bank’s Tourmaline Bio TRML Stock Holding History

WesBanco Bank’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-26,000	Closed	-$416K	–	711
2025 Q2	$416K	Buy	+26,000	New	+$421K	0.01%	514

Other funds holding TRML

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

WesBanco Bank's TRML Position: Q3 2025 in Review

WesBanco Bank sold out of Tourmaline Bio (TRML) in Q3 2025, closing a stake of 26,000 shares — an estimated $416K sold.

WesBanco Bank first reported a position in TRML in Q2 2025 and held it in 1 quarter. The position peaked at $416K in Q2 2025. 134 funds tracked by Wall St. Rank hold TRML as of Q3 2025.

WesBanco Bank reported no remaining Tourmaline Bio position as of Q3 2025 after selling out during the quarter.
WesBanco Bank sold 26,000 Tourmaline Bio shares in Q3 2025, an estimated $416K.
WesBanco Bank first reported a position in Tourmaline Bio in Q2 2025 and held it in 1 quarter.
WesBanco Bank's Tourmaline Bio position peaked at $416K in Q2 2025.
134 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2025.

Based on WesBanco Bank's 13F filing for Q3 2025, filed 6 Nov 2025.